In Vivo Lentivirus-based Macrophage Reprogramming Service for Cancer

Targeting Macrophages in Cancer Immunotherapy

In the tumor microenvironment (TME), macrophages are the most abundant leucocytes and predominant immune cells. Macrophages play a critical role in stimulating tumor growth and regulating TME formation. There is compelling evidence to support the significant role of macrophages in various aspects of tumor development, including angiogenesis, metastasis, evasion of the immune system, and the occurrence of side effects related to therapy. Many researchers focus on macrophage studies in anti-tumor immunotherapy.

Fig.1 Reprogramming of macrophages and activation of immune responses.¹

Our In Vivo Lentivirus-based Macrophage Reprogramming Service for Cancer

To promote the application of macrophages into anti-tumor immunotherapy, Creative Biolabs successfully developed an in vivo lentivirus-based macrophage reprogramming service for cancer. Our engineered macrophage integrates the lentivirus vector and sustained transgene expression and can target several factors such as cytokines that are crucial for tumor processes. In the macrophage reprogramming service, we construct diverse lentivirus vectors targeting different cancer targets to engineer macrophages in vivo. In addition, with the support of our top-ranking services, solid expertise, and rich experience, we are confident in delivering the desirable outcomes for every customer in a rapid turnaround.

Applications

Here are two applications for in vivo lentivirus-based macrophage reprogramming.

IFN-α Lentivirus Delivery	IL-12 Lentivirus Delivery
Fig.2 IFN-α lentivirus delivery to liver macrophages.²	Fig.3 IL-12 lentivirus delivery to human macrophages.³
IFN-α lentivirus delivery system delivers a lentiviral vector expressing IFN-α to the target site to selectively engineer liver macrophages for the purpose of achieving therapeutic efficacy.	The IL-12 lentivirus delivery system delivers a lentiviral vector expressing IL-12 to human macrophages to express therapeutic payloads and achieve therapeutic efficacy.

Benefits

Diverse targets to generate different lentiviral vectors for in vivo macrophage engineering.
Quick timeframes enable the duplication of outcomes while also saving time.
Solid expertise and rich experience enable the smooth running of global customers' projects.
Top-ranking services customized to meet global customers' diverse demands.

Case Show

Case 1: IFN-α Lentivirus Delivery to Liver Macrophages

IF=50.3

Macrophages: Kupffer cells and TAMs

Highlights: In this study, the researchers discuss a gene transfer strategy that specifically targets hepatic macrophages. By administering a single intravenous infusion of a well-tolerated lentiviral vector (LV) that expresses interferon-alpha (IFN-α), this strategy has been shown to provide rapid protection against colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). At the same time, the therapeutic response in various mouse models of liver metastasis is being investigated.

Fig.4 In vivo engineered liver macrophages enable effective IFN-α production.²

As a pioneer in the industry, Creative Biolabs draws on years of priceless experience and a wealth of professional expertise to create cutting-edge instruments that improve cancer treatment and quality of life in general.

If you are considering participating in our in vivo lentivirus-based macrophage reprogramming service for cancer and would like more details, please feel free to contact us.

References

Mantovani, Alberto, et al. "Macrophages as tools and targets in cancer therapy." Nature Reviews Drug Discovery 21.11 (2022): 799-820.
Kerzel, Thomas, et al. "In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases." Cancer Cell (2023).
Brempelis, Katherine J., et al. "Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses." Journal for immunotherapy of cancer 8.2 (2020).